Abstract
The antinociceptive effect of interleukin-2 gene on rat carrageenan-induced pain was explored using different delivery methods. Intrathecal (i.t.) or plantar s.c. delivery of plasmid harbouring the interleukin-2 gene produced a marked antinociceptive effect, which was maintained up to 6 days; the administration of recombinant human interleukin-2 only had a transitory effect. The antinociceptive effect lasted longer and was more potent when the interleukin-2 gene was administered i.t. than when delivered s.c. The effect of the interleukin-2 gene was related to its protein expression, was dose dependent, and could be potentiated by liposome. The results suggest that the interleukin-2 gene has a good prospect for clinical use.
MeSH terms
-
Afferent Pathways / drug effects*
-
Afferent Pathways / metabolism
-
Animals
-
Cation Exchange Resins / pharmacology
-
DNA, Complementary / genetics
-
Dose-Response Relationship, Drug
-
Gene Expression / physiology
-
Genetic Therapy / methods*
-
Genetic Vectors / genetics
-
Genetic Vectors / pharmacology*
-
Genetic Vectors / therapeutic use
-
Indicators and Reagents / pharmacology
-
Injections, Spinal / methods
-
Injections, Subcutaneous
-
Interleukin-2 / genetics*
-
Interleukin-2 / pharmacology
-
Lipids / pharmacology
-
Male
-
Nociceptors / drug effects*
-
Nociceptors / metabolism
-
Pain / drug therapy*
-
Pain / genetics
-
Pain / metabolism
-
Plasmids / genetics
-
Plasmids / pharmacology
-
Plasmids / therapeutic use
-
Posterior Horn Cells / drug effects*
-
Posterior Horn Cells / metabolism
-
Rats
-
Rats, Sprague-Dawley
Substances
-
Cation Exchange Resins
-
DNA, Complementary
-
Indicators and Reagents
-
Interleukin-2
-
Lipids
-
Lipofectamine